Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?
8 children with acute myelogenous leukaemia were brought into remission with a induction regimen containing cytosin arabinoside (Ara-C), 6-thioguanine and adriamycin given as the DNA complex. After remissions were obtained, the children were consolidated with high-dose Ara-C (2 g/m2 every 12 h for 6 doses) and were given 50 000 IU of vitamin A daily as an inducer of differentiation. All children are in continuous relapse-free survival for periods of 5 to 29 months (mean 14 months).
D002648:Child; D003561:Cytarabine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D014801:Vitamin A / Q000627:therapeutic use*
D003561:Cytarabine; D014801:Vitamin A